Charcot-Marie-Tooth disease (CMT) is a rare, chronic, progressive motor and sensory neuropathy affecting the peripheral nervous system. This study will explore the real-world impact of CMT. The trial is a digital study of approximately 2000 people in 6 countries with CMT ≥18 years. Participants will use a smartphone application to check eligibility, provide consent and contribute data. The dataset will include a personal profile, covering demographics, lifestyle, diagnosis and treatment and a selection of validated generic and disease-specific instruments. Participants will provide data for up to 2 years. Data analysis will be conducted upon registration of the 1000th participant and at 12-month intervals from launch. This study is designed to help researchers and clinicians understand the real-world impact of CMT and the unmet needs of patients. ClinicalTrials.gov identifier: NCT03782883
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Thomas, F. P., Saporta, M., Attarian, S., Sevilla, T., Mascaró, R. S., Fabrizi, G. M., … Boutalbi, Y. (2021). Patient-reported impact of Charcot-Marie-Tooth disease: Protocol for a real-world digital lifestyle study. Neurodegenerative Disease Management, 11(1), 21–33. https://doi.org/10.2217/nmt-2020-0044